Merck's Keytruda patent cliff pressure eases
The discussion argued Moderna's cancer vaccine success gives Merck another sizable product, easing pressure from its upcoming Keytruda patent cliff.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.